Avcı Böcek <em>Macrolophus pygmaeus </em> (Rambur)’un Laboratuvar Koşullarında Farklı Avlar Üzerindeki Gelişimi

Macrolophus pygmaeus Rambur (Hemiptera: Miridae) beyazsinekler, yaprakbitleri, akarlar ve galeri sinekleri ile beslenen polifag avcı bir türdür. Bu çalışma ile zararlı türlerden Aphis gossypii, Myzus persicae (Hemiptera: Aphididae), Trialeurodes vaporariorum (Hemiptera: Aleyrodidae), Ephestia kuehniella (Lepidoptera: Pyralidae) yumurtaları ve aynı zamanda kontrol olarak patlıcan bitkisi üzerinde Macrolophus pygmaeus’ un beslenme davranışları ve ömür uzunlukları belirlenmiştir. Bu çalışma 26±1ºC, %60±5 nem ve 16:8 aydınlatmalı iklim odalarında yürütülmüştür. Sonuç olarak,  patlıcanla beslenen M. pygmaeus’un %54’ü ergin olmadan ölmüş, diğer avlarla beslenen tüm bireyler ergin olmuşlardır. Patlıcanla beslenen bireylerin ilk nimf önemi, dördüncü ve beşinci nimf dönemi ve toplam nimf dönemi diğer avlardan daha uzun sürmüş ve istatiksel olarak farklı bulunmuştur. Patlıcan ve A. gossypii ile beslenen avcının ikinci ve üçüncü nimf dönemleri istatistiksel olarak aynı bulunmuş ve gelişme süreleri diğer avlardan daha uzun olmuştur. Predatörün dördüncü nimf dönem periyodu besine bağlı olarak farklılık göstermiş olup gelişim süresinin en uzun bulunduğu besin patlıcan olmuştur. Bunu A. gossypii, M. persicae, E. kuehniella yumurtası ve T. vapororiorum takip etmiş ve toplam nimf dönemleri sırasıyla 19.56, 18.12, 15.50, 14.96 ve 13.64 gün olarak bulunmuştur

TRopBank: Turkish PropBank V2.0

In this paper, we present and explain TRopBank “Turkish PropBank v2.0”. PropBank is a hand-annotated corpus of propositions which is used to obtain the predicate-argument information of a language. Predicate-argument information of a language can help understand semantic roles of arguments. “Turkish PropBank v2.0”, unlike PropBank v1.0, has a much more extensive list of Turkish verbs, with 17.673 verbs in total.Publisher's Versio

On building the largest and cross-linguistic Turkish dependency corpus

In this paper, we aim to introduce the dependency annotation process of the largest and the only cross-linguistic Turkish dependency treebank which was translated from the original Penn Treebank corpus. Within the scope of this project, 16.400 sentences have been morphologically and semantically annotated, and the dependency relations were manually carried out by a team of linguists. It is hoped that this project will serve as a base for a successful dependency parser and a system which can automatically perform the bi-directional conversion between constituency and dependency trees.Publisher's Versio

Creating a syntactically felicitous constituency treebank for Turkish

In this study, Bakay et. al [1] and Yildiz et. al.'s [2] work on Turkish constituency treebanks were developed further. Compared to the previous work, the most prominent feature of this study is the fact that every annotation and refinement process is held manually. In addition, constituency treebank created as a result of this study abides by the syntactic rules and typologic features of Turkish while the trees created by previous studies convey only the translated and simply inverted trees that completely ignore the syntactic properties of Turkish. The methodology followed in this study resulted in a significantly more accurate representation of Turkish language and simpler, relatively flatter trees. The straightforward style of trees in this study reduces the complexity and offers a better training dataset for learning algorithms.Publisher's Versio

Morpholex Turkish: a morphological Lexicon for Turkish

MorphoLex is a study in which root, prefix and suffixes of words are analyzed. With MorphoLex, many words can be analyzed according to certain rules and a useful database can be created. Due to the fact that Turkish is an agglutinative language and the richness of its language structure, it offers different analyzes and results from previous studies in MorphoLex. In this study, we revealed the process of creating a database with 48,472 words and the results of the differences in language structure

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET